Intercept Pharmaceuticals v. Zenara Pharma: Obeticholic Acid Patent Dispute Ends in Consent Judgment
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Intercept Pharmaceuticals, Inc. v. Zenara Pharma Private Limited |
| Case Number | 1:22-cv-01215 (D. Del.) |
| Court | U.S. District Court for the District of Delaware |
| Duration | Sep 2022 – Mar 2024 537 days |
| Outcome | Plaintiff Win — Consent Judgment & Permanent Injunction |
| Patents at Issue | |
| Accused Products | Obeticholic acid tablets (5 mg and 10 mg) |
Case Overview
The Parties
⚖️ Plaintiff
A biopharmaceutical company specializing in bile acid chemistry, with a substantial IP portfolio around obeticholic acid (OCA).
🛡️ Defendant
An India-based generic pharmaceutical manufacturer seeking approval to market generic obeticholic acid tablets in 5 mg and 10 mg dosages.
The Patents at Issue
This landmark case involved six U.S. patents spanning obeticholic acid composition, formulation, and method claims. These patents collectively form a layered exclusivity strategy — a common approach in Hatch-Waxman litigation where innovators stack various patent types to extend commercial protection.
- • US9238673B2 (App. No. 13/919734)
- • US10047117B2 (App. No. 14/947658)
- • US10052337B2 (App. No. 15/139138)
- • US10174073B2 (App. No. 15/496398)
- • US10751349B2 (App. No. 16/248512)
- • US10758549B2 (App. No. 16/787796)
Developing a generic drug?
Check if your formulation might infringe these or related pharmaceutical patents before filing your ANDA.
The Verdict & Legal Analysis
Outcome
On March 6, 2024, Judge Noreika entered a Consent Judgment and Permanent Injunction by stipulation of both parties. The judgment reflects a negotiated resolution codified in a private Settlement Agreement. Specific financial terms were not publicly disclosed. Zenara and its affiliates are permanently enjoined from making, using, selling, offering to sell, importing, or distributing the Zenara Products, except as specifically authorized by the Settlement Agreement. The FDA retains authority to grant final approval of ANDA No. 214855.
Key Legal Issues
This action arose as a classic Hatch-Waxman ANDA infringement dispute under 35 U.S.C. § 271(e)(2). Upon Zenara’s filing of ANDA No. 214855 with a Paragraph IV certification, Intercept exercised its statutory right to file suit within 45 days, triggering a 30-month stay of FDA approval. The settlement, structured as a consent judgment with injunctive relief, strongly suggests Intercept negotiated from a position of patent strength, preserving its commercial position against generic competition.
Freedom to Operate (FTO) Analysis for Pharmaceutical IP
This case highlights critical IP risks in pharmaceutical development. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this litigation.
- View all related patents in this technology space
- See which companies are most active in obeticholic acid IP
- Understand claim construction patterns for FXR agonists
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own pharmaceutical formulation.
- Input your drug substance or formulation details
- AI identifies potentially blocking patents & ANDA filings
- Get actionable risk assessment report
High Risk Area
Obeticholic acid formulations & derivatives
6 Patents Asserted
In obeticholic acid portfolio
Strategic FTO Planning
Crucial for ANDA filers
✅ Key Takeaways
Six-patent assertion strategies in Hatch-Waxman litigation create compounding negotiation leverage and increase the cost-risk calculus for generic challengers.
Search related case law →Consent judgments with retained court jurisdiction provide durable, court-enforceable protection beyond private contract remedies.
Explore precedents →Frequently Asked Questions
Six U.S. patents were asserted: US9238673B2, US10047117B2, US10052337B2, US10174073B2, US10751349B2, and US10758549B2 — all covering obeticholic acid compositions, formulations, or methods of use.
The parties reached a negotiated settlement agreement resolving all claims. The consent judgment codified agreed injunctive relief preventing Zenara from commercializing its ANDA-referenced obeticholic acid tablets without authorization.
The outcome reinforces that multi-patent Hatch-Waxman enforcement, combined with strategic Delaware venue selection, remains highly effective at securing negotiated market entry control — often without requiring a trial on the merits.
Ready to Strengthen Your Patent Strategy?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision.
References
- PACER — Case No. 1:22-cv-01215, D. Del.
- USPTO Patent Full-Text Database — Intercept’s patent portfolio
- FDA Orange Book — Obeticholic acid listings
- Cornell Legal Information Institute — 35 U.S.C. § 271(e)(2)
- FTC v. Actavis, Inc. — Supreme Court Decision (2013)
This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For platform capabilities, visit PatSnap.